The MMKD could regulate the biomarker levels of AD with increasing Aβ42 and decreasing tau protein in cerebrospinal fluid, which might be mediated by the alteration of gut mycobiome, gut bacteria, and SCFAs [139,165]. The gene discussed is MAPT; the disease is Alzheimer disease.